Natera (NTRA) Stock Forecast & Price Target

Natera is viewed favorably because it dominates a more than $15B MRD market with over 90% share, and Signatera’s reimbursed clinical volumes rose 60% in 2025 while 2026 revenue from pharma could reach about $70M with further acceleration possible later. Its moat is reinforced by superior ultra-sensitive testing, planned prospective data from trials slated to read out in 2027, and reimbursement advantages that make replication difficult for competitors. The outlook is also supported by improving unit economics, with Signatera ASP at $1,275 versus a Medicare rate of $3,590, COGS down more than $100 since 2022, and a path toward 70%+ gross margins and 25%+ EBIT margins over time.

Natera is viewed negatively because its growth story depends heavily on MRD adoption and ASP expansion, yet both could stall as penetration in established uses like CRC adjuvant already exceeds 50% and the broader opportunity may be more saturated than expected. Competition is intensifying across MRD and women’s health, with multiple well-capitalized rivals and persistent share battles that could erode Natera’s reimbursement-led advantage. Catalyst execution has also been inconsistent, with delayed ACOG and NCCN support and setbacks like ALTAIR, while MRD ASPs rising from roughly $500 to $1,250 over the past five years may not continue linearly toward the $2,000 goal.